Tuesday - May 13, 2025

LOGIN  |  REGISTER
Astria Therapeutics

Invivyd to Participate in Upcoming Investor Conferences

September 06, 2023 | Last Trade: US$0.80 0.15 23.82

WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will present at the following investor conferences:

H.C. Wainwright 25th Annual Global Investment Conference
Fireside Chat Date: Monday, September 11, 2023
Fireside Chat Time: 3:00 PM ET
Location: New York, NY

Morgan Stanley 21st Annual Global Healthcare Conference
Fireside Chat Date: Wednesday, September 13, 2023
Fireside Chat Time: 12:55 PM ET
Location: New York, NY

Live webcasts of the fireside chats will be available in the investor section of the company's website at investors.invivyd.com and will be archived for approximately 90 days following the events.

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. ​​Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit https://invivyd.com/ to learn more.

Contacts:

Scott Young
(781) 208-1747
syoung@invivyd.com 

Gabriella Linville-Engler
(781) 208-0160
gengler@invivyd.com 

Chimerix

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page